- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06277115
Acute and Long-term Effects of CPAP in OSA
Acute, Intermediate and Long-term Effects of CPAP Therapy in Obstructive Sleep Apnoea: a Two-phase Interventional Trial.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background and Aim: Obstructive sleep apnoea (OSA) is a prevalent sleep-related breathing disorder. OSA is associated with daytime sleepiness, impaired quality of life, and adverse cardiovascular outcome. OSA can be effectively treated with nocturnal continuous positive airway pressure (CPAP) that restores normal breathing during sleep by preventing upper airway collapse. However, many patients in whom treatment of OSA is indicated are not able to adhere to CPAP, and the consequences of untreated OSA seem to differ between OSA phenotypes. Therefore, treatment alternatives to CPAP and a better understanding of treatment implications in different phenotypes of OSA are important targets in this research field. Thus, effective and controlled study designs are needed to address these research questions. Conventional randomised controlled CPAP trials are limited by low CPAP adherence resulting in an underestimation of the treatment effect. In addition, the impracticability of withholding an effective treatment from symptomatic patients resulting in inclusion of less symptomatic and patients with less severe OSA has limited the conclusions from previous trials. The CPAP therapy withdrawal model was introduced to allow studying the pathophysiological consequences of OSA and treatment effects of CPAP in an effective and controlled way. Optimally treated patients previously diagnosed with OSA established on CPAP therapy are included and undergo a short-term therapy interruption. A therapy withdrawal results in recurrence of OSA and pathophysiological changes can be attributed to OSA in this controlled model. However, it is uncertain whether the consequences of OSA during a short-term CPAP therapy withdrawal are comparable to long-term consequences of untreated OSA.
The aim of this two-phase interventional trial is to assess the effects of intermediate and long-term CPAP therapy as well as acute CPAP therapy withdrawal resulting in OSA recurrence compared to longstanding untreated OSA on cardiovascular and symptom outcomes in moderate and severe OSA. The objective is to study the comparability of conventional CPAP therapy trials with the CPAP withdrawal model in terms of evaluating relevant cardiovascular and patient-centred outcomes in OSA.
The investigators hypothesise that the treatment effect of CPAP in previously treatment-naïve patients with OSA - if adherent to CPAP - will support the same conclusions on OSA pathophysiology and therapy effects as a short-term CPAP withdrawal in treatment-adherent patients having a recurrence of OSA in response to CPAP withdrawal and thus support the use of this effective CPAP withdrawal model to use as future study design in interventional trials in OSA. It is hypothesised that the CPAP withdrawal is non-inferior to conventional CPAP trials in studying the effect on blood pressure and OSA-symptoms.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Esther Irene I Schwarz, MD
- Phone Number: +41442553828
- Email: estherirene.schwarz@usz.ch
Study Contact Backup
- Name: Joël J Herzig
- Email: joel.herzig@usz.ch
Study Locations
-
-
-
Zurich, Switzerland, 8091
- Recruiting
- University Hospital Zürich
-
Contact:
- Joël J Herzig
- Email: joel.herzig@usz.ch
-
Contact:
- Esther I Schwarz, MD
- Phone Number: 0041442553828
- Email: estherirene.schwarz@usz.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years
- Untreated moderate or severe OSA with an apnoea-hypopnoea-index (AHI) of ≥ 20/h and an oxygen desaturation index (>3%-dips) of ≥ 20/h in an in-laboratory sleep study
- Epworth Sleepiness Scale Score ≥7/24 points
- Indication for CPAP therapy
- Written informed consent
Exclusion Criteria:
- Moderate or more severe obstructive or restrictive ventilatory disorder (FEV1 or FVC < 70%)
- Heart failure
- Other types of sleep-related breathing disorders, e.g. sleep-associated hypoventilation, central sleep apnoea, Cheyne Stoke's Breathing
- Hypoxic or hypercapnic respiratory failure (awake paO2 < 9 kPa or paCO2 > 6 kPa)
- Active treatment for OSA (CPAP, mandibular advancement device, hypoglossal nerve stimulation)
- Current professional driver or previous sleepiness-related accidents
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Single arm (therapy initiation followed by therapy withdrawal)
Continuous positive airway pressure (CPAP)
|
Nocturnal continuous positive airway pressure therapy is the gold standard treatment for symptomatic OSA.
It provides positive pressure via a nasal or oronasal mask to prevent upper airway collapse during sleep.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nocturnal systolic blood pressure
Time Frame: at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Ambulatory blood pressure monitoring (ABPM)
|
at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Epworth Sleepines Scale Score (ESS)
Time Frame: at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Subjective sleepiness, ESS min-max 0-24 points and ESS >10 indicating pathological daytime sleepiness
|
at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
48h, 24h, diurnal and nocturnal systolic and diastolic blood pressure
Time Frame: at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
ABPM
|
at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Office systolic and diastolic blood pressure
Time Frame: at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Morning office blood pressure
|
at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
48h, 24h, diurnal, nocturnal and office heart rate
Time Frame: at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Heart rate from ABPM, office measurement and from sleep studies
|
at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Heart rate variability in the time and frequency domain (CV, RMSSD, pRR50, LF, HF, LF/HF)
Time Frame: at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Measures of heart rate variability (daytime and nighttime)
|
at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Blood pressure variability (BPV, systolic and diastolic)
Time Frame: at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
BPV from ABPM and beat-to-beat blood pressure measurement
|
at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Baroreflex sensitivity (BRS)
Time Frame: at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Finometer
|
at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Arterial stiffness
Time Frame: at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
ABPM
|
at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Measures of nocturnal hypoventilation (median and maximal transcutaneous partial pressure of CO2 = tcpCO2)
Time Frame: at baseline and at least 8 weeks of CPAP as well as after 2 weeks of CPAP withdrawal
|
Sleep study parameters
|
at baseline and at least 8 weeks of CPAP as well as after 2 weeks of CPAP withdrawal
|
Measures of nocturnal hypoxaemia (mean nocturnal oxygen saturation = ¢SpO2)
Time Frame: at baseline and at least 8 weeks of CPAP as well as after 2 weeks of CPAP withdrawal
|
Sleep study parameters
|
at baseline and at least 8 weeks of CPAP as well as after 2 weeks of CPAP withdrawal
|
Measures of nocturnal hypoxaemia (time spent with SpO2 below 90% = t<90)
Time Frame: at baseline and at least 8 weeks of CPAP as well as after 2 weeks of CPAP withdrawal
|
Sleep study parameters
|
at baseline and at least 8 weeks of CPAP as well as after 2 weeks of CPAP withdrawal
|
Measures of nocturnal hypoxaemia (hypoxic burden)
Time Frame: at baseline and at least 8 weeks of CPAP as well as after 2 weeks of CPAP withdrawal
|
Sleep study parameters
|
at baseline and at least 8 weeks of CPAP as well as after 2 weeks of CPAP withdrawal
|
Measures of OSA severity (apnoea-hypopnoea-index)
Time Frame: at baseline and at least 8 weeks of CPAP as well as after 2 weeks of CPAP withdrawal
|
Sleep study parameters
|
at baseline and at least 8 weeks of CPAP as well as after 2 weeks of CPAP withdrawal
|
Measures of OSA severity (oxygen-desaturation index)
Time Frame: at baseline and at least 8 weeks of CPAP as well as after 2 weeks of CPAP withdrawal
|
Sleep study parameters
|
at baseline and at least 8 weeks of CPAP as well as after 2 weeks of CPAP withdrawal
|
Sleepiness (Stanford Sleepiness Scale (SSS))
Time Frame: at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Questionnaire; 7-point Likert scale to quantify a patient's sleepiness at the time the questionnaire is completed; highr scores indicate more sleepiness
|
at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Fatigue (fatigue severity scale (FSS))
Time Frame: at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Questionnaire; 9 items, higher score indicates more fatigue
|
at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Disease-specific quality of life (Functional Outcomes of Sleep Questionnaire (FOSQ))
Time Frame: at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Questionnaires, Disease-specific quality of life questionnaire to determine functional status in adults; measures are designed to assess the impact of disorders of excessive sleepiness on multiple activities of everyday living and the extent to which these abilities are improved by effective treatment; 30 items; higher scores are better
|
at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Superoxide dismutase
Time Frame: at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Marker of oxidative stress (U/ml)
|
at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Urinary catecholamines
Time Frame: at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Epinephrine and norepinephrine in morning urine (nnmol/mmol)
|
at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Pulse rise index (>6 beats per minute)
Time Frame: at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
from nocturnal oximetry
|
at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Nocturnal oxymetry measures (¢SpO2, t<90, ODI-3%, ODI-4%)
Time Frame: at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
nocturnal pulse oximetry
|
at baseline and at 2 and at least 8 weeks of CPAP as well as after 1 and after 2 weeks of CPAP withdrawal
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Esther I Schwarz, MD, University of Zurich
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BASEC Nr. 2020-02002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obstructive Sleep Apnea of Adult
-
Cryosa, Inc.Active, not recruitingObstructive Sleep Apnea of AdultPanama, Paraguay
-
State Key Laboratory of Respiratory DiseaseCompletedObstructive Sleep Apnea of AdultChina
-
Somnics, Inc.UnknownObstructive Sleep Apnea of AdultTaiwan
-
Cryosa, Inc.RecruitingObstructive Sleep Apnea of AdultPanama
-
Idorsia Pharmaceuticals Ltd.CompletedObstructive Sleep Apnea of AdultGermany
-
Essam FathiCompletedObstructive Sleep Apnea of AdultEgypt
-
Instituto Nacional de Ciencias Medicas y Nutricion...Emory University; Universidad Nacional Autonoma de MexicoRecruitingObstructive Sleep Apnea of AdultMexico
-
Northwestern UniversitySibel Health Inc.Completed
-
Arizona State UniversityMayo Clinic; National Institute of Nursing Research (NINR)CompletedObstructive Sleep Apnea of AdultUnited States
-
Nyxoah S.A.Nyxoah Pty. Ltd.Not yet recruitingObstructive Sleep Apnea of AdultAustralia
Clinical Trials on Continuous positive airway pressure (CPAP)
-
Indiana UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Eileen R. ChasensCompletedSleep Apnea, Obstructive | Diabetes Mellitus, Type 2United States
-
Sociedad Española de Neumología y Cirugía TorácicaCompletedObstructive Sleep ApneaSpain
-
St. Olavs HospitalNorwegian University of Science and TechnologyCompletedChronic Disease | Cluster HeadacheNorway
-
McGill UniversityCentre hospitalier de l'Université de Montréal (CHUM); Philips Respironics; Multiple... and other collaboratorsCompletedObstructive Sleep Apnea-hypopnea in Multiple Sclerosis PatientsCanada
-
Chinese Pulmonary Vascular Disease Research GroupCompletedObstructive Sleep Apnea | Coronary Heart DiseaseChina
-
Eileen R. ChasensTerminatedObstructive Sleep Apnea | Type 2 DiabetesUnited States
-
Chinese University of Hong KongCompleted
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedSleep Apnea, Obstructive | Fatigue | SarcoidosisItaly
-
ResMedCompleted